Julie Patterson, NPC's Senior Director of Research, to Discuss Unintended Consequences of the IRA at DIA 2025

At the DIA 2025 Global Annual Meeting in Washington D.C. on June 16, NPC Senior Director of Research Julie Patterson will join a forum discussion on “Unintended Consequences: Effects of the Inflation Reduction Act on the Future of Pharmaceutical Innovation.”

Monday June 16, 2025 | 11:00am - 12:00pm

Unintended Consequences: Effects of the Inflation Reduction Act on the Future of Pharmaceutical Innovation

Among the largest areas of concern with the Inflation Reduction Act (IRA) are potential unintended consequences to pharmaceutical innovation. This forum will convene industry experts to explore the impact of and potential adjustments to the IRA.

Chair: 

• Sarah Martin, PhD, MS, Eli Lilly and Company

Speakers:

• Gregory Daniel, PhD, MPH,  Eli Lilly and Company
• Ryan Gough, Woodberry Associates
• Richard Xie, PhD, RA Capital Management
• Julie Ann Patterson, PharmD, PhD, National Pharmaceutical Council